Background: Late infantile neuronal ceroid lipofuscinosis (LINCL) is associated with progressive
ples in the literature of CT, MRI, and MRS imaging studies of the CNS in children with LINCL, [15] [16] [17] [18] other than the Hamburg University rating scale of disease severity in patients residing in Germany and Switzerland based on clinical assessment of language, motor function, seizures, and vision, 19 the natural progression of LINCL is not well characterized. As the basis of planning a gene therapy study of LINCL, 20, 21 we have had the opportunity to make 32 assessments of 18 children with LINCL using a battery of measurements relating to their neurologic status, including MRI and MRS imaging. The present study summarizes these data and establishes a more comprehensive clinical disease severity rating scale focused on the CNS dysfunction, contributing to the understanding of the progressive deterioration in this disorder.
METHODS Study group. The study group consisted of 18 children (9 boys, 9 girls) with confirmed LINCL. DNA analysis of the CLN2 mutations was available for all children prior to inclusion into the study. The initial evaluation included a detailed neurologic examination by a pediatric neurologist, funduscopic examination by an ophthalmologist, and MRI/MRS imaging of the brain. Fourteen of the children were subsequently reassessed 18 to 365 days after the initial evaluation, for a total of 32 assessments of the 18 children. The parents of all study children provided informed consent and the research protocol was reviewed and approved by the Institutional Review Board at Weill Medical College of Cornell University.
LINCL CNS severity assessment. LINCL CNS severity and progression were evaluated using two scales: a modified form of the Hamburg LINCL scale based on a scale originally developed by Steinfeld et al. 19 to assess LINCL disease progression, but modified to assess only the CNS, not the ophthalmologic manifestations of the disease 20 ; and a newly developed Weill Cornell LINCL scale, which is an expanded severity scale assessing the degree of CNS dysfunction that includes swallowing dysfunction, gait, motor, and language abnormalities.
The modified Hamburg LINCL scale assesses motor function, seizure activity, and language skills. Each of these individual scales is ranked from 0 to 3 and then all individual ratings are added to provide a total rating with 0 being the most severe and 9 the mildest. The following ratings for the individual scales were used: Seizure scale: 3 ϭ no seizures/3-month period; 2 ϭ 2 seizures/3 month period; 1 ϭ 1 seizure/ month; 0 ϭ Ͼ1 seizure/month; Motor scale: 3 ϭ walks normally; 2 ϭ frequent falls, clumsiness obvious; 1 ϭ no unaided walking or crawling only; 0 ϭ immobile, mostly bedridden; and Language scale: 3 ϭ normal; 2 ϭ recognizably abnormal; 1 ϭ hardly understandable; and 0 ϭ unintelligible or no language. The ratings were summarized for the total disability, and grouped as 0 to 4 severe, 5 to 6 moderate, 7 to 8 mild, and 9 normal.
The Weill Cornell LINCL scale expands the modified Hamburg LINCL scale to include the assessment of swallowing function ("feeding scale"), gait ("gait scale"), motor system abnormalities ("motor scale"), and speech abnormalities ("language scale"). The following ratings for the individual scales were used: Feeding scale: 0 ϭ gastrostomy-dependent; 1 ϭ moderate swallowing dysfunction; 2 ϭ mild swallowing dysfunction; 3 ϭ no swallowing dysfunction; Gait scale: 0 ϭ nonambulatory; 1 ϭ abnormal (spastic, bradykinetic, or ataxic), and unable to ambulate independently; 2 ϭ abnormal (spastic, bradykinetic or ataxic), but able to ambulate independently; 3 ϭ normal; Motor scale: 0 ϭ myoclonus and one of chorea or tremor or athetosis (referred to as chorea/ tremor/athetosis) and positive Babinski reflex; 1 ϭ two of myoclonus, chorea/tremor/athetosis, or positive Babinski reflex; 2 ϭ one of myoclonus, chorea/tremor/athetosis, or positive Babinski reflex; 3 ϭ none of myoclonus, chorea/tremor/ athetosis, or positive Babinski reflex; and Language scale: 0 ϭ unintelligible words or no speech; 1 ϭ barely understandable speech (severe dysarthria or very few meaningful words); 2 ϭ abnormal speech (abnormal articulation or decreased vocabulary; and 3 ϭ normal speech. The ratings were summarized for an index of the total disability, with a maximum score of 12 for normal and 0 for most severe (table 1) .
Ophthalmology examination. Funduscopic evaluation
was performed by slit lamp examination and direct ophthalmoscopy using a 20 diopter lens by an ophthalmologist.
MRI/MRS.
All image data were acquired on a 3.0 Tesla MRI system (GE Medical Systems, Milwaukee, WI). Imaging included T1-weighted, T2-weighted, and fluidattenuated inversion recovery (FLAIR) sequences. For the MRI and MRS imaging measurements only experimentally valid data points are presented (n ϭ 27 scans for NAA, n ϭ 28 for ventricular volume, n ϭ 26 for gray matter volume, and n ϭ 32 for CADC). N-acetylaspartate (NAA), creatine, and lactate levels in the CNS were extracted from the MRS data set. Volumetric assessments of the ventricles were per formed on T1-weighted data sets. To assess gray and white matter volume a spoiled gradient recalled pulse sequence (SPGR) was employed. The cortical apparent diffusion coefficient (CADC) was measured with a spin-echo diffusion weighted (DWI) echoplanar (EPI) sequence implemented over the entire brain (for more details, see supplemental E-Methods on the Neurology Web site at www.neurology.org).
Statistics. Data are reported as mean Ϯ SEM and median.
Correlation coefficients were calculated using linear regression and significance was determined by analysis of variance. Differences in regression with age or time since initial manifestation of the disease were assessed by comparatively analyzing the slopes of the linear regression.
RESULTS

Characteristics of the study population.
The children were from the United States, Canada, England, Australia, and Germany. The ages of the children at the initial evaluation ranged from 3.3 to 13.8 years (6.3 Ϯ 0.6 years; median 5.7 years; table 2). There were four sibling pairs.
Eight different mutations of the CLN2 gene were present in 35 alleles; no mutation was detected in one allele of BD-10. The sibling pairs each had the same mutations. The most frequent mutation was the splice mutation G3556C present in 18 alleles (50%); 7 of the children were homozygous for this allele. All of the homozygous mutations were found in the children from England and Australia. The second most frequent mutation was C3670T, which results in a premature stop codon, and was present in 8 alleles (25%). Two children were homozygous for this mutation.
LINCL history. The diagnosis of LINCL was made at an average age of 4.0 Ϯ 0.2 years (range 2.0 to 5.3 years, median 4.0; table 3). The diagnosis was based on biochemical testing of the TPP-1 levels in fibroblasts or leukocytes and genetic analysis. Three of the children were assessed due to previous diagnosis in an affected sibling; these children were tested before the onset of symptoms.
The average age at the onset of seizures was 3.3 Ϯ 0.2 years (median 3.1 years, range 2.0 to 6.3 years). The type of seizures included myoclonic, complex partial, and generalized tonic clonic seizures with the majority of the children experiencing more than one seizure type. All of the children received anticonvulsive therapy with control of the seizures at the time of the initial presentation. The reported onset of the language abnormalities was 3.0 Ϯ 0.2 years (median 3.0 years, range 1.5 to 4.8 years). Some of the children never acquired normal language skills and were diagnosed in their second year of life with speech delay. The reported onset of motor dysfunction was at 3.5 Ϯ 0.2 years (median 3.5 years, range 1.9 to 5.0 years). For the children with complete loss of the ability to walk at the time of the assessment, the age at which they became wheelchair-bound was 5.7 Ϯ 0.3 years (median 5.7 years, range 4.3 to 6.5 years). Feeding difficulties were common; only 17% of the children had no feeding problems, 67% were fed via a gastrostomy tube due to their swallowing dysfunction. Disease progression varied in some of the four sibling pairs, indicating that there may be confounding factors such as modifier genes important for disease progression besides the mutation alone. No change in the progression of the clinical phenotypic pattern was seen related to either of the two frequent mutations C3670T or G3556C nor with the sibling pair (BD02 and BD03), carrying the G3085A mutation, which has been previously associated with a less severe phenotype.
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LINCL severity and neurologic characteristics. The total ratings of the modified Hamburg LINCL scale of the study children at the time of initial evaluation ranged from 3 to 6 (table E-1 on the Neurology Web site at www.neurology.org). All but one child (BD-17) in the severe category (total score of 0 to 4) had a seizure score of 3, as defined by no seizures within the previous 3-month pe- riod. None of the children had a score of 1, possibly reflecting the efficacy of their antiepileptic drug regimens, which resulted in decreased sensitivity at the lower end of the scale. The modified Hamburg LINCL scale declined with the age of the children (figure E-1A). In our study population, the scores of the modified Hamburg LINCL scale were mostly within the 5th to 95th percentile range as reported by Steinfeld et al. 19 (gray shaded area, figure E-1). For those children outside the range described by Steinfeld et al., 19 all were shifted to the right (i.e., older age for the same degree of severity), all were older (Ͼ7 years), and all were in the severe category. In general, this "right shift" was due to lack of seizure activity (i.e., seizure score 3), perhaps associated with effective antiseizure therapy. Over the course of the study, three of the children died due to progression of the disease. There were no significant differences as a function of age in the rating scale among the two most frequent CLN2 mutations G3556C (figure E-1B) and C3670T (figure E-1C; p ϭ 0.87).
All children had neurologic abnormalities at the time of the initial presentation (table 4). Strength in upper or lower extremities was decreased in all of the children evaluated at an age older than 4 years. Muscle stretch reflexes were increased in most children, with a few showing normal or decreased muscle stretch reflexes. The plantar response was mostly "upgoing," reflecting upper motor neuron involvement in this disease. Dystonia in the form of athetoid movements was observed only in one child during one evaluation. Dyskinesia of the tongue was seen in 13% (4 of 32) of the assessments. The gait abnormalities of the children who were still ambulatory were mostly of spastic and ataxic type. Myoclonus was seen in 69% (22 of 32) of the assessments. Tremors and chorea were seen less frequently, in 25% (8 of 32) and 16% (5 of 31) of the assessments. *Listed in the order of the initial evaluation; , □, ‚, E used to identify sibling pairs. †Age in years at initial evaluation. ‡Mutations are named by location in the gene 7, 8 with the wild type nucleotide before and mutant nucleotide after. G3556C is a mutation in the splice junction also referred to as IVS5-1GϾC or c.509-1GϾC. The C3670T mutation is a premature stop codon also called R208X or c.622CϾT. § Medical problems unrelated to the known clinical manifestations of LINCL. [1] [2] [3] [4] [5] Premature stop codon at amino acid 104. ¶ Missense (ArgϾGln) mutation at amino acid 127.
**Splicing mutation in intron 8 splice donor. † †Missense mutation (LeuϾPro) in amino acid 355. ‡ ‡The diagnosis of LINCL for this patient was based on the TPP-1 deficiency and the presence of a known mutation for LINCL on the other allele. § § Compound heterozygote with splicing mutation splice acceptor for intron 1 and in frame deletion of amino acids 275-279.
LINCL ϭ late infantile neuronal ceroid lipofuscinosis; W ϭ white; Cb ϭ Caribbean.
Weill Cornell LINCL scale. The new Weill Cornell LINCL scale, which expands the assessment of the neurologic abnormalities compared to the modified Hamburg LINCL scale, correlated better with the age of the children compared to the modified Hamburg LINCL scale (r 2 ϭ 0.55; p Ͻ 0.0001 for Weill Cornell LINCL scale vs r 2 ϭ 0.44; p Ͻ 0.0001 for modified Hamburg LINCL scale; figure 1A . The Weill Cornell scale separated the individual assessments over a broad area within the range of the scale. Compared to the age progression observed with the modified Hamburg LINCL scale, the slope of the decline with age was steeper with the Weill Cornell LINCL scale (y ϭ Ϫ0.85 ϫ ϩ 8.2 for the Weill Cornell CNS scale vs y ϭ Ϫ0.36 ϫ ϩ 6.3 for the modified Hamburg LINCL scale; p Ͻ 0.05), suggesting that this scale may detect deviations toward a decreased rate of disease progression more readily and may thus be the more valuable of the two scales to assess effects of novel therapies on disease progression. As seen for the modified Hamburg LINCL scale, progression with age of the Weill Cornell LINCL scale was not different for the two frequent genotypes G3556C (figure 1B) and C3670T ( figure  1C , p ϭ 0.83).
Both LINCL scales correlated also with the time since initial clinical manifestation of the disease, as determined by the chronological age at the time of evaluation minus the age when seizures or language or motor abnormalities were first observed (figure 2 and figure E-2). Again, as seen for the correlation with age, the Weill Cornell LINCL scale correlated better with time since initial clinical presentation (r 2 ϭ 0.53; p Ͻ 0.0001; figure 2) compared to the modified Hamburg LINCL scale (r 2 ϭ 0.35; p Ͻ 0.0001; figure E-2). Also, the individual assessments were separated more over the range of the Weill Cornell LINCL scale with steeper slope of decline (y ϭ Ϫ1.03 ϫ ϩ 6.5) compared to the modified Hamburg LINCL scale (y ϭ Ϫ0.41 ϫ ϩ 5.5). As seen for the relation of the two frequent genotypes G3556C
and C3670T with age, no difference was observed in the increase of severity with either of these two genotypes as a function of time since initial manifestation of the disease (not shown; p Ͼ 0.6 for the comparisons for both LINCL severity scales). Brain imaging. The T1-weighted MR images showed progressive global atrophy of the gray matter with increasing degree of ventricular enlargement becoming more marked with severity of the disease (decreasing scores on the modified Hamburg and Weill Cornell LINCL scales; figure 3 ). For example, MRI of a moderate patient with a score of 6 on the modified Hamburg LINCL scale and 8 on the Weill Cornell LINCL scale showed minimal white matter hyperintensities and no gross gray matter involvement (figure 3, A and B). Some minimal gray matter changes and involvement with atrophy were visible in a moderate patient with scores of 5 on the modified Hamburg LINCL and 5 on the Weill Cornell LINCL scale (figure 3, C and D). In contrast, even more pronounced global atrophy was present in children in the severe category one with a score of 4 on the modified Hamburg LINCL scale and 3 on the Weill Cornell LINCL scale (figure 3, E and F) and another with a score of 3 on the modified Hamburg LINCL scale and 1 on the Weill Cornell LINCL scale (figure 3, G and H).
Imaging measurements and age. Ten different measurements of the MRI or MRS assessments were used to quantify disease progression, including quantification of levels of cortical N-acetylaspartate (NAA; a metabolite reflecting the amount of neuronal cells by MRS); NAA/creatine and lactate as measured by MRS; ventricular, white matter, and gray matter volume, quantified from T1-weighted MR images and each calculated as an absolute volume and as a % of total brain volume; and the cortical apparent diffusion coefficient (CADC) by diffusion weighted MRI of cortical brain ADC histograms. NAA levels, gray matter volume, and % gray matter volume of total brain volume declined with age ( figure 4 , A, E, F), reflecting the loss of neurons with progression of the disease. In contrast, CADC, a measurement reflecting the microscopic self-diffusion of H 2 O molecules (H 2 O diffusivity increases with a lack of structural restrictions at the cellular level due to neuronal degeneration), increased with age and disease progression ( figure 4B ). Ventricular volume and % ventricular volume of total brain volume also increased with age, reflecting the expansion of the ventricular space secondary to neuronal loss (figure 4, C and D). Interestingly, white matter volume and % white matter volume of total brain volume also increased with age, suggesting that this increase could either be attributed to a relative increase in white matter due to gray matter loss or to an absolute increase in white matter volume. The correlations of the eight imaging measurements with age were best for ventricular volume Ͼ % gray matter volume Ͼ CADC Ͼ % ventricular volume Ͼ NAA Ͼ % white matter volume Ͼ white matter volume Ͼ gray matter volume. Lactate and NAA/creatine, other MRS measurements, correlated similarly to NAA with age (r 2 ϭ 0.25; p Ͻ 0.01 for NAA/ creatine and r 2 ϭ 0.42; p Ͻ 0.001 for lactate; not shown).
The correlations of the 10 imaging measurements as a function of time since initial clinical manifestation of the disease (figure 5) showed a similar pattern as observed for the correlations of the imaging measurements with age. Correlations were best with ventricular volume (figure 5C) Ͼ CADC (figure 5B) Ͼ % ventricular volume ( figure 5D ) Ͼ % gray matter volume (figure 5F) Ͼ NAA (figure 5A) Ͼ gray matter volume (figure 5E) Ͼ % white matter volume (figure 5H) Ͼ white matter volume (figure 5G), suggesting that the time since disease manifestation is reflected better by increased ventricular volume and CADC, as compared to decreased gray matter volume and NAA. Lactate correlated well with the time since initial manifestation of the disease (r 2 ϭ 0.57; p Ͻ 0.0001) and the correlation for NAA/creatine with the time since initial manifestation of the disease was comparable to that of NAA with the time since clinical manifestation of the disease (r 2 ϭ 0.35; p Ͻ 0.001; not shown).
Imaging measurements and disease severity scales.
The correlation of the imaging measurements as a function of the modified Hamburg LINCL scale was best for % ventricular volume (figure E-3D) Ͼ % gray matter volume (Figure E-3F) Ͼ ventricular volume (figure E-3C) Ͼ gray matter volume (figure E-3E) Ͼ NAA (figure E-3A) Ͼ CADC (figure E-3B) Ͼ % white matter volume (figure E-3H) Ͼ white matter volume (figure E-3G). All imaging measurements except gray matter volume correlated less well with the modified Hamburg LINCL scale compared to age and time since initial clinical manifestation, and % white matter volume and white matter volume correlated similarly poorly compared to time since initial clinical manifestation. These observations suggest that the modified Hamburg LINCL scale reflects disease severity and progression as determined by the imaging measurements less well compared to age and time since clinical manifestation. Correlations of the imaging measurements with the Weill Cornell LINCL scale were better for six measurements (NAA, ventricular volume, % ventricular volume, gray matter volume, % gray matter volume, and % white matter volume) compared to the correlations with the modified Hamburg LINCL scale (figure 6, A, C through F, H). The correlation of the Weill Cornell LINCL scale with CADC ( figure 6B ) was comparable to the correlation with the modified Hamburg LINCL scale and there was no good correlation with white matter volume (figure 6G) as seen for the modified Hamburg LINCL scale. The best correlation was with the % ventricular volumes ( figure 6D) . Interestingly, the second and fourth best correlations were with % gray matter volume ( figure 6F ) and gray matter volume (figure 6E), followed by the correlation with NAA ( figure  6A ), suggesting that these primary measurements of neuronal loss are reflected better as a function of the Weill Cornell LINCL scale compared to as a function of age or time since initial clinical manifestation of the disease. The lower correlations for CADC with both severity scales compared to the other three imaging measurements were partially affected by the very high CADC value in the oldest child (figure 6B). Neither of the two LINCL scales correlated well with lactate (r 2 Ͻ 0.08; p Ͼ 0.15 for both comparisons; not shown) nor with NAA/creatine (r 2 ϭ 0.28; p Ͻ 0.01 for the modified Hamburg LINCL scale and r 2 ϭ 0.30; p Ͻ 0.01 for the Weill Cornell LINCL scale; not shown).
DISCUSSION
The clinical presentation and progression of LINCL have been well documented. [1] [2] [3] [4] [5] 19 Symptoms usually appear in early childhood and consist of seizures and loss of motor function, language, and vision. Progression of the disease is rapid over the next few years with complete loss of motor function by 6 years and death at 8 to12 years. Exceptions from this disease pattern have been described for a few patients with rare CLN2 mutations who had delayed onset of symptoms. 1, 7, 8 The children in our cohort followed the classic pattern with the mean onset of language abnormalities at 3.0 years, seizures at 3.2 years, and motor abnormalities at 3.6 years. Some of the children never completely acquired language capacity beyond verbalization of a few words and had been diagnosed initially with speech delay.
Disease severity scales to assess disease progression have been developed for various forms of neuronal ceroid lipofuscinosis. 19, 22, 23 A comprehensive clinical rating scale has been developed for juvenile NCL, including assessment of motor, behavioral, and functional capability. 22, 23 For LINCL, which develops early in life and progresses rapidly, it is challenging to develop such a comprehensive disease severity scale. The only disease severity scale developed to date is the LINCL severity scale from Steinfeld et al., 19 which includes the assessment of seizures, motor dysfunction, language abnormality, and vision.
In the context of our interest in developing a gene therapy strategy to treat the CNS manifestations of LINCL, we modified the scale created by Steinfeld et al. 19 to focus only on the CNS manifestations of the disease referred to here as the modified Hamburg LINCL scale. The agespecific ratings of our cohort using the modified Hamburg LINCL scale compared well with the one from Steinfeld et al. 19 for the younger children, but most of the children older than 6 years of age were outside the 95th percentile range. Most of these deviations were due to the high rating on the seizure scale of the modified LINCL scale, likely reflecting optimized antiseizure management or inability of the brain to generate seizures due to advanced neuronal degeneration. This feature of the modified Hamburg LINCL scale further limited the phenotypic range of the scale.
A clinical rating instrument, which is able to identify more subtle differences in disease progression of children with LINCL, would be desirable to study the natural progression of the disease and is critically important for the assessment of novel therapeutic interventions, as the window for assessing disease progression is only a few years from the onset of symptoms to development of a vegetative state. [1] [2] [3] [4] [5] 19 In this context, the new Weill Cornell CNS scale was developed to help identify phenotypic differences over a broader range. The Weill Cornell CNS scale, consisting of a more comprehensive neurologic assessment compared to the modified Hamburg LINCL scale and excluding events prior to the time of the assessment, such as onset of seizures, correlated better with age and the time since clinical manifestations of the disease compared to the modified Hamburg LINCL scale. The individual assessments also separated over a wider range with a steeper decline compared to the modified Hamburg LINCL scale. These features make this new scale suitable to detect deviations to a slower rate of decline with age more readily and make it particularly valuable for the assessment of the effect of novel therapies on disease progression.
To date, at least 52 different mutations in the CLN2 gene have been associated with the LINCL phenotype (http://www.ucl.ac.uk/ncl). Two of these mutations, the missense mutation C3670T (R208X) and the splicing mutation G3556C (IVS5-1 GϾC) , account for at least 60% of all disease alleles. A study including patients from Germany and Switzerland found C3670T in 42% and G3556C in 25% of the mutant alleles. 19 The 5th and 95th percentile range of the modified LINCL CNS scale based on the data of Steinfeld et al. 19 used to assess age-specific disease severity is based on patients from that study carrying exclusively the C3670T or G3556C mutation. 19 All of the CLN2 mutations in our patient population have been previously reported in the NCL mutation database (http://www.ucl.ac.uk/ncl). In our study population, 25% of the alleles were C3670T, with both patients from Germany being homozygous for this mutation, and 50% of the alleles were G3556C, with all the children from England (except BD-17 whose mother was from the Caribbean), Canada, and Australia having at least one allele with this mutation. Although the sample size precluded a comprehensive assessment of the relationship of genotype with phenotype, we did not observe a difference in the progression of the clinical phenotypic pattern related to either C3670T or G3556C, the two most frequent mutations. Later onset of disease or milder progression have been associated in the literature with a few mutations (R447H, S153P, R127Q, and the intron splice mutation T523-1GøA). 19, [24] [25] [26] Two of the children, a sibling pair, carried R127Q (G3085A). The milder disease course, previously described for this mutation in a compound heterozygous patient with C3670T/ R127Q, 19 was not observed for the compound heterozygous G3556C/R127Q children in our study.
Anecdotal MRI brain imaging studies have been reported for living patients with LINCL, demonstrating progressive gray matter atrophy prominent in the infratentorial regions. 15, 17, 18, 27, 28 In a postmortem MRI study of 16 patients with LINCL, characteristic MRI findings were enlarged cerebral and cerebellar sulci as well as dilated ventricles, 15 similar to the MRI changes in the present study. Also changes in periventricular white matter, the only finding in the less severely affected children in our cohort, have been previously described in children with more advanced disease. 15, 17, 18 Brain imaging with MRI and MRS provides the tools and opportunity to assess disease severity and to monitor disease progression for neurodegenerative disorders quantitatively. None of this has been reported in a comprehensive and quantitative fashion for LINCL to date, but MRI, MRS, and SPECT analysis have been employed to characterize disease progression in eight patients with infantile NCL (CLN1). MRI and MRS showed abnormal findings before the disease was clinically apparent, and SPECT analysis showed cortical hypoperfusion and loss of benzodiazepine receptors with the onset of clinical manifestations. 29 Gray matter volume, % gray matter volume, and NAA, assessing the presence of neurons, decreased with age and severity of the disease, whereas ventricular volume, % ventricular volume, and CADC, assessing consequences of the neuronal loss, increased with age and severity of the disease. The % white matter volumes increased with age and severity of the disease. However, the data did not allow us to distinguish whether the increase in the % white matter volume was absolute or relative to the brain atrophy attributable to the gray matter loss. Of all the MRI measurements evaluated, ventricular volume or % ventricular volume correlated the best with age and the severity scales, suggesting that the measurement of ventricular volumes may be the best MRI measurement to assess disease progression.
In two small studies with LINCL, MRS assessment showed decreased NAA/creatine ratios in three patients, 18 and decreased NAA and elevated lactate in one patient. 16 The NAA measurements in our cohort showed variability between children and also between repeat evaluations of the same child, indicating that this measurement can serve as a marker for overall disease progression in a cohort of patients, but may not be suitable to follow disease progression in individual patients.
The noninvasive instruments used to assess brain structure and degeneration in this study were useful in pointing out that in LINCL gray matter volume and NAA decrease with disease progression, in contrast to white matter volume, ventricular volume, and whole brain diffusion capacity (CADC), which increase with disease progression. These data are consistent with ongoing neuronal loss contributing to the progressive brain atrophy and clinical deterioration evident in LINCL.
Overall, the present study provides an improved understanding of LINCL and provides new tools to assess severity and progression of the disease. By using a novel, more comprehensive disease severity scale, assessing the neurologic manifestations of the disease, and employing quantitative imaging measurements, in particular the assessment of ventricular volumes, this study also provides a basis for the evaluation of novel therapeutic strategies such as gene and stem cell therapy.
NOTE ADDED IN PROOF
Analysis of the MRS data from a subset of scans (n ϭ 10) with data available from voxels corresponding to thalamic tissue showed that thalamic NAA/Cr ratios correlated better with patient age (r 2 ϭ 0.45), Modified Hamburg LINCL scale (r 2 ϭ 0.60), and Weill
Cornell LINCL scale (r 2 ϩ 0.69) compared to the cortical region of interest reported in the manuscript (r 2 ϭ 0.25, 0.28, and 0.30, respectively). These newer analyses suggest that MRS measurements of thalamus may provide greater sensitivity as a marker to identify the progression of Batten disease.
